Neovascular GlaucomaNCT07201415
Minimally Invasive Suprachoroidal Drainage for the Treatment of Neovascular Glaucoma
A study testing minimally invasive suprachoroidal drainage in people with Neovascular Glaucoma, run by Zhongnan Hospital at 1 site in China.
Trial summary
To explore the efficacy and safety of minimally invasive suprachoroidal drainage for the treatment of advanced neovascular glaucoma Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Neovascular Glaucoma
- What is being tested?
- minimally invasive suprachoroidal drainage
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2025to 1 Mar 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Advanced (angle-closure) neovascular glaucoma with poorly controlled intraocular pressure (IOP > 21mmHg) after medical or surgical treatment
Who cannot join
- Various other types of glaucoma (including primary open-angle glaucoma, primary open-closed glaucoma, normal tension glaucoma, juvenile glaucoma, congenital glaucoma, other special types of glaucoma, etc.)
- Eye infection within two weeks before surgery
- Non-glaucomatous intraocular diseases that affect intraocular pressure (choroidal hemorrhage or detachment, retinal detachment, lens subluxation, thyroid eye disease, clinically significant macular edema, eye tumors, etc.)
- Visual acuity of non-study eyes < 0.05
- Congenital or acquired factors lead to ciliary body anatomical abnormalities
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Exploratory Study of the Efficacy and Safety of Minimally Invasive Supraporoidal Drainage for Advanced Neovascular Glaucoma
To explore the efficacy and safety of minimally invasive suprachoroidal drainage for the treatment of advanced neovascular glaucoma
Read the detailed description
To explore the efficacy and safety of minimally invasive supraporcular drainage in the treatment of advanced neovascular glaucoma, and to record the various basic diseases, ocular conditions, lifestyle, inflammatory markers and other parameters of NVG patients. To compare the safety and efficacy of new surgical methods and traditional surgical methods in order to find an effective treatment for neovascular glaucoma
- Conditions
- Neovascular Glaucoma
- Being tested
- minimally invasive suprachoroidal drainage
- Keywords
- Neovascular glaucoma, Retinal Vein Occlusion, Diabetic Retinopathy, Treatment
- Medical subject headings
- Glaucoma, Neovascular, Retinal Vein Occlusion, Diabetic Retinopathy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
minimally invasive suprachoroidal drainageProcedure or surgery
minimally invasive suprachoroidal drainage
| Study group | Role | What they receive |
|---|---|---|
| Surgical Treatment Group | Experimental | The patient will undergo a minimally invasive suprachoroidal drainage procedure Receives: Procedure: minimally invasive suprachoroidal drainage |
What is being measured
The primary outcome is the main question the study is designed to answer.
Ocular biological parameters
intraocular pressure
Measured: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
Ocular biological parameters
visual acuity
Measured: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
Surgical outcome measures
use of intraocular pressure lowering drugs
Measured: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
The success rate of surgery was evaluated according to the specific value of intraocular pressure after surgery
Complete success was defined as IOP within the normal range with no drug dependence, conditional success was defined as IOP within the normal range with drug dependence, and failure was defined as the rest
Measured: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
Secondary outcomes (2)
The effective rate of surgery was evaluated according to the amplitude of IOP reduction after surgery and the change in the number of IOP-lowering drugs
Amplitude of IOP reduction: IOP change/initial IOP.The total number of IOP lowering drugs was recorded based on the number of active ingredients
Measured: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
Surgical outcome measures
complications
Measured: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2025
- Study start1 Jan 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion1 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neovascular GlaucomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zhongnan Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07201415
- Sponsor's protocol ID
- 20250904
- Status last verified
- Sep 2025
- First submitted
- 10 Sep 2025
- Last updated
- 1 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Exploratory Study of the Efficacy and Safety of Minimally Invasive Supraporoidal Drainage for Advanced Neovascular Glaucoma
- ClinicalTrials.gov ID
- NCT07201415
- Acronym / sponsor ID
- 20250904
- Conditions
- Neovascular Glaucoma
- Keywords
- Neovascular glaucoma, Retinal Vein Occlusion, Diabetic Retinopathy, Treatment
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Zhongnan HospitalUniversity, hospital or other
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 1 Mar 2027 (estimated)
- First posted
- 1 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To explore the efficacy and safety of minimally invasive suprachoroidal drainage for the treatment of advanced neovascular glaucoma
Detailed description
To explore the efficacy and safety of minimally invasive supraporcular drainage in the treatment of advanced neovascular glaucoma, and to record the various basic diseases, ocular conditions, lifestyle, inflammatory markers and other parameters of NVG patients. To compare the safety and efficacy of new surgical methods and traditional surgical methods in order to find an effective treatment for neovascular glaucoma
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Surgical Treatment Group | Experimental | Procedure: minimally invasive suprachoroidal drainageThe patient will undergo a minimally invasive suprachoroidal drainage procedure |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Advanced (angle-closure) neovascular glaucoma with poorly controlled intraocular pressure (IOP > 21mmHg) after medical or surgical treatment
Key exclusion criteria (5 listed)
- Various other types of glaucoma (including primary open-angle glaucoma, primary open-closed glaucoma, normal tension glaucoma, juvenile glaucoma, congenital glaucoma, other special types of glaucoma, etc.)
- Eye infection within two weeks before surgery
- Non-glaucomatous intraocular diseases that affect intraocular pressure (choroidal hemorrhage or detachment, retinal detachment, lens subluxation, thyroid eye disease, clinically significant macular edema, eye tumors, etc.)
- Visual acuity of non-study eyes < 0.05
- Congenital or acquired factors lead to ciliary body anatomical abnormalities
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| minimally invasive suprachoroidal drainageminimally invasive suprachoroidal drainage | Procedure or surgery | Surgical Treatment Group |
Primary outcome
Ocular biological parameters
Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
intraocular pressure
Ocular biological parameters
Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
visual acuity
Surgical outcome measures
Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
use of intraocular pressure lowering drugs
The success rate of surgery was evaluated according to the specific value of intraocular pressure after surgery
Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
Complete success was defined as IOP within the normal range with no drug dependence, conditional success was defined as IOP within the normal range with drug dependence, and failure was defined as the rest
2 secondary outcomes
The effective rate of surgery was evaluated according to the amplitude of IOP reduction after surgery and the change in the number of IOP-lowering drugs
Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
Surgical outcome measures
Time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Oct 2025.
Related trials for Neovascular Glaucoma
RecruitingObservational study
Observation of Iris Blood Flow Via OCTA in Diabetic Neovascular Glaucoma
Neovascular Glaucoma, Type 2 Diabetes
RecruitingObservational study
Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
Neovascular Glaucoma
Recruiting
Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT
Glaucoma, Neovascular, Vascular Endothelial Growth Factor Overexpression
Active, not recruitingPhase 1
KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial
Neovascular Glaucoma, Neovascularization
Enrolling by invitationObservational study
INTEGRAL Study: A Longitudinal Study of Surgeries and Lasers in Glaucoma: Long-term Results and Success Predictors Analysed From a Large-scale Retrospective and Prospective Glaucoma Register
Glaucoma Open-Angle, Glaucoma Eye
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing minimally invasive suprachoroidal drainage in people with Neovascular Glaucoma, run by Zhongnan Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 1 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Ocular biological parameters (time frame: 1 day, 1 week, 1 month, 3 months, and 6 months after surgery). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2025.